Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. OBJECTIVE: To determine the efficac...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA
Auteurs principaux: Tap, William D., Wagner, Andrew J., Schöffski, Patrick, Martin-Broto, Javier, Krarup-Hansen, Anders, Ganjoo, Kristen N., Yen, Chueh-Chuan, Abdul Razak, Albiruni R., Spira, Alexander, Kawai, Akira, Le Cesne, Axel, Van Tine, Brian A., Naito, Yoichi, Park, Se Hoon, Fedenko, Alexander, Pápai, Zsuzsanna, Soldatenkova, Victoria, Shahir, Ashwin, Mo, Gary, Wright, Jennifer, Jones, Robin L.
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2020
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139275/
https://ncbi.nlm.nih.gov/pubmed/32259228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.1707
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires